NCT02220894 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 637
- group Id
- BG001
- value
- 637
- group Id
- BG002
- value
- 1274
- units
- Participants
- groups
- description
- Participants received pembrolizumab 200 mg by IV infusion on Day 1 Q3W for a maximum of 35 cycles (21-day cycles)
- id
- BG000
- title
- Pembrolizumab
- description
- Participants received carboplatin at target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\^2 by IV infusion on Day 1 Q3W
- id
- BG001
- title
- Chemotherapy (SOC Treatment)
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.9
- value
- 62.5
- group Id
- BG001
- spread
- 9.4
- value
- 63.1
- group Id
- BG002
- spread
- 9.7
- value
- 62.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 187
- group Id
- BG001
- value
- 185
- group Id
- BG002
- value
- 372
- title
- Female
- measurements
- group Id
- BG000
- value
- 450
- group Id
- BG001
- value
- 452
- group Id
- BG002
- value
- 902
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 15
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 189
- group Id
- BG001
- value
- 187
- group Id
- BG002
- value
- 376
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 23
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 398
- group Id
- BG001
- value
- 412
- group Id
- BG002
- value
- 810
- title
- White
- measurements
- group Id
- BG000
- value
- 30
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 49
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 197
- group Id
- BG001
- value
- 192
- group Id
- BG002
- value
- 389
- title
- ECOG PS=0
- measurements
- group Id
- BG000
- value
- 439
- group Id
- BG001
- value
- 445
- group Id
- BG002
- value
- 884
- title
- ECOG PS=1
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- ECOG PS=2
- description
- Participants were assessed for ECOG PS: Grade 0: Fully active, able to carry on all pre-disease performance without restriction; Grade 1: Restricted in physically strenuous activity but ambulatory \& able to carry out work of a light or sedentary nature; Grade 2: Ambulatory \& capable of all selfcare but unable to carry out any work activities, up \& about more than 50% of waking hours; Grade 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; Grade 4: Completely disabled, cannot carry on any selfcare, totally confined to bed or chair or Grade 5: Dead.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 299
- group Id
- BG001
- value
- 300
- group Id
- BG002
- value
- 599
- title
- TPS=≥50%
- measurements
- group Id
- BG000
- value
- 114
- group Id
- BG001
- value
- 105
- group Id
- BG002
- value
- 219
- title
- TPS=20-49%
- measurements
- group Id
- BG000
- value
- 224
- group Id
- BG001
- value
- 232
- group Id
- BG002
- value
- 456
- title
- TPS=1-19%
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- TPS=<1%
- description
- Participants were assessed for their PD-L1 tumor expression status by immunohistochemistry assay using tumor tissue from an archival or newly obtained biopsy. Participants with a tumor proportion score (TPS) were classified as follows: ≥50% = PD-L1 strongly positive; 1-49% = PD-L1 weakly positive; and \<1% = PD-L1 negative.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Programmed Cell Death-Ligand 1 (PD-L1) Tumor Status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 242
- group Id
- BG001
- value
- 249
- group Id
- BG002
- value
- 491
- title
- Squamous
- measurements
- group Id
- BG000
- value
- 395
- group Id
- BG001
- value
- 388
- group Id
- BG002
- value
- 783
- title
- Non-squamous
- description
- Participants were classified according to tumor histology: Squamous or Non-squamous. The tumor histology determined potential treatment regimen.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Tumor Histology
- unit Of Measure
- Participants
- population Description
- The Baseline Analysis Population consisted of all randomized participants who were alive at the time of randomization and had a Tumor Proportion Score (TPS) ≥1%.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 637
- group Id
- BG001
- value
- 637
- group Id
- BG002
- value
- 1274
- units
- Participants
- groups
- description
- Participants received pembrolizumab 200 mg by IV infusion on Day 1 Q3W for a maximum of 35 cycles (21-day cycles)
- id
- BG000
- title
- Pembrolizumab
- description
- Participants received carboplatin at target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\^2 by IV infusion on Day 1 Q3W
- id
- BG001
- title
- Chemotherapy (SOC Treatment)
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.9
- value
- 62.5
- group Id
- BG001
- spread
- 9.4
- value
- 63.1
- group Id
- BG002
- spread
- 9.7
- value
- 62.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 187
- group Id
- BG001
- value
- 185
- group Id
- BG002
- value
- 372
- title
- Female
- measurements
- group Id
- BG000
- value
- 450
- group Id
- BG001
- value
- 452
- group Id
- BG002
- value
- 902
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 15
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 189
- group Id
- BG001
- value
- 187
- group Id
- BG002
- value
- 376
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 23
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 398
- group Id
- BG001
- value
- 412
- group Id
- BG002
- value
- 810
- title
- White
- measurements
- group Id
- BG000
- value
- 30
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 49
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 197
- group Id
- BG001
- value
- 192
- group Id
- BG002
- value
- 389
- title
- ECOG PS=0
- measurements
- group Id
- BG000
- value
- 439
- group Id
- BG001
- value
- 445
- group Id
- BG002
- value
- 884
- title
- ECOG PS=1
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- ECOG PS=2
- description
- Participants were assessed for ECOG PS: Grade 0: Fully active, able to carry on all pre-disease performance without restriction; Grade 1: Restricted in physically strenuous activity but ambulatory \& able to carry out work of a light or sedentary nature; Grade 2: Ambulatory \& capable of all selfcare but unable to carry out any work activities, up \& about more than 50% of waking hours; Grade 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; Grade 4: Completely disabled, cannot carry on any selfcare, totally confined to bed or chair or Grade 5: Dead.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 299
- group Id
- BG001
- value
- 300
- group Id
- BG002
- value
- 599
- title
- TPS=≥50%
- measurements
- group Id
- BG000
- value
- 114
- group Id
- BG001
- value
- 105
- group Id
- BG002
- value
- 219
- title
- TPS=20-49%
- measurements
- group Id
- BG000
- value
- 224
- group Id
- BG001
- value
- 232
- group Id
- BG002
- value
- 456
- title
- TPS=1-19%
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- TPS=<1%
- description
- Participants were assessed for their PD-L1 tumor expression status by immunohistochemistry assay using tumor tissue from an archival or newly obtained biopsy. Participants with a tumor proportion score (TPS) were classified as follows: ≥50% = PD-L1 strongly positive; 1-49% = PD-L1 weakly positive; and \<1% = PD-L1 negative.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Programmed Cell Death-Ligand 1 (PD-L1) Tumor Status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 242
- group Id
- BG001
- value
- 249
- group Id
- BG002
- value
- 491
- title
- Squamous
- measurements
- group Id
- BG000
- value
- 395
- group Id
- BG001
- value
- 388
- group Id
- BG002
- value
- 783
- title
- Non-squamous
- description
- Participants were classified according to tumor histology: Squamous or Non-squamous. The tumor histology determined potential treatment regimen.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Tumor Histology
- unit Of Measure
- Participants
- population Description
- The Baseline Analysis Population consisted of all randomized participants who were alive at the time of randomization and had a Tumor Proportion Score (TPS) ≥1%.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle